Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 10/20 | 0.80 |
| ▸ | MAPT | P10636 | 7/20 | 0.80 |
| ▸ | BACE1 | P56817 | 4/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.80 |
| ▸ | MMP9 | P14780 | 3/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.80 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.80 |
| ▸ | MAOA | P21397 | 2/20 | 0.80 |
| ▸ | MAOB | P27338 | 2/20 | 0.80 |
| ▸ | TOP2A | P11388 | 2/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.80 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.80 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.80 |
| ▸ | STAT3 | P40763 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13295258 | 0.95 | APP (0.76) | APPMAPTBACE1NFKB1MMP9 | |
| SCHEMBL30663618 | 0.93 | APP (0.86) | APPMAPTBACE1NFKB1MMP9 | |
| SCHEMBL29123540 | 0.91 | APP (0.74) | APPMAPTBACE1NFKB1MMP9 | |
| Ammonia Solution, Strong SCHEMBL28303751 | 0.91 | APP (0.74) | APPMAPTBACE1NFKB1MMP9 | |
| SCHEMBL31498024 | 0.91 | APP (0.74) | APPMAPTBACE1NFKB1MMP9 | |
| SCHEMBL27686673 | 0.90 | TOP2A (0.89) | APPMAPTBACE1NFKB1MMP9 | |
| SCHEMBL1374497 | 0.90 | TOP2A (0.89) | APPMAPTBACE1NFKB1MMP9 | |
| Curcumin SCHEMBL8440 | 0.89 | APP (1.00) | APPMAPTBACE1NFKB1MMP9 | |
| Curcumin SCHEMBL2804734 | 0.89 | APP (1.00) | APPMAPTBACE1NFKB1MMP9 | |
| Curcumin SCHEMBL17629819 | 0.89 | APP (1.00) | APPMAPTBACE1NFKB1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084637-A | Curcumin and preparation method of symmetrical derivative thereof | 肇庆巨元生化有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-9271493-B2 | Methods for microbial biofilm destruction | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-01 | — | — | US | disclosed |
| EP-1441697-B1 | CONDUCTANCE OF IMPROPERLY FOLDED PROTEINS THROUGH THE SECRETORY PATHWAY AND RELATED METHODS FOR TREATING DISEASE | UNIV YALE (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20130338233-A1 | METHODS FOR MICROBIAL BIOFILM DESTRUCTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2013-12-19 | — | — | US | disclosed |
| US-8058314-B2 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | YALE UNIVERSITY (US) | 2011-11-15 | — | — | US | disclosed |
| US-20080025921-A1 | Conductance of Improperly Folded Proteins Through the Secretory Pathway And Related Methods For Treating Disease | N-FOLD LLC | 2008-01-31 | — | — | US | disclosed |
| WO-2005086954-A2 | CONDUCTANCE OF IMPROPERLY FOLDED PROTEINS THROUGH THE SECRETORY PATHWAY AND RELATED METHODS FOR TREATING DISEASE | YALE UNIVERSITY (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20040266883-A1 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | YALE UNIVERSITY | 2004-12-30 | — | — | US | disclosed |
| EP-1441697-A2 | CONDUCTANCE OF IMPROPERLY FOLDED PROTEINS THROUGH THE SECRETORY PATHWAY AND RELATED METHODS FOR TREATING DISEASE | YALE UNIVERSITY (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030236300-A1 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | YALE UNIVERSITY | 2003-12-25 | — | — | US | disclosed |
| EP-0861223-B1 | PROCESS FOR THE SYNTHESIS OF CURCUMIN-RELATED COMPOUNDS | GENEPRINT INC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030149113-A1 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | YALE UNIVERSITY | 2003-08-07 | — | — | US | disclosed |
| WO-2003049717-A2 | CONDUCTANCE OF IMPROPERLY FOLDED PROTEINS THROUGH THE SECRETORY PATHWAY AND RELATED TREATMENTS OF DISEASES | YALE UNIVERSITY (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-0861223-A1 | PROCESS FOR THE SYNTHESIS OF CURCUMIN-RELATED COMPOUNDS | Geneprint, Inc. (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5679864-A | REACTING 2,4-DIKETONE WITH COMPLEXING AGENT TO PRODUCE ENOLIC REACTANT, ADDING AROMATIC ALDEHYDE, AMINE CATALYST, NEUTRALIZING | GENE PRINT INC. (US) | 1997-10-21 | — | — | US | disclosed |
| WO-1997016403-A1 | PROCESS FOR THE SYNTHESIS OF CURCUMIN-RELATED COMPOUNDS | GENEPRINT, INC. (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266883-A1 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | HSPA5, ERP44, ATP2A2 | APP 79/4885MAPT 1763/4885BACE1 833/4885 |
| US-20130338233-A1 | METHODS FOR MICROBIAL BIOFILM DESTRUCTION | UROD, ESD, DNMT1 | APP 2142/4885MAPT 3324/4885BACE1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.